• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Avalo Therapeutics Inc.

    4/5/24 4:00:56 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVTX alert in real time by email
    SC 13G 1 deeptrack-avtx032724.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*



    AVALO THERAPEUTICS, INC.

    (Name of Issuer)

     

    Common Stock, $0.001 Par Value

    (Title of Class of Securities)

     

    05338F306

    (CUSIP Number)

     

     

    March 27, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)

    x Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  05338F306
     SCHEDULE 13G
    Page 2 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Deep Track Capital, LP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) x
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    114,775
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    114,775
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    114,775*
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.99%
    12
    TYPE OF REPORTING PERSON
     
    IA, OO

    * Includes 1,940.68125 Series C Non-Voting preferred stock which may be converted to common stock at a conversion ratio of 1 Series C Non-Voting preferred stock to 1,000 common stock and 1,164,408 warrants exercisable to common stock, both subject to a 9.99% Beneficial Ownership Limitation. The Issuer shall not effect any conversion of any share of Series C Non-Voting Preferred Stock or exercise of any Warrants, to the extent that, after giving effect to such attempted conversion set forth on an applicable Notice of Conversion (as defined in the Certificate of Designation) with respect to the Series C Preferred Stock or to such exercise, such Holder would be a beneficial owner of Common Stock beneficially owned by the Holder for purposes of Section 13(d) or Section 16 of the Exchange Act and the applicable rules and regulations of the Commission would beneficially own a number of shares of Common Stock in excess of the Beneficial Ownership Limitation.

     


     

    CUSIP No.  05338F306
     SCHEDULE 13G
    Page 3 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Deep Track Biotechnology Master Fund, Ltd.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) x
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    114,775
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    114,775
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    114,775*
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.99%
    12
    TYPE OF REPORTING PERSON
     
    CO

    * Includes 1,940.68125 Series C Non-Voting preferred stock which may be converted to common stock at a conversion ratio of 1 Series C Non-Voting preferred stock to 1,000 common stock and 1,164,408 warrants exercisable to common stock, both subject to a 9.99% Beneficial Ownership Limitation. The Issuer shall not effect any conversion of any share of Series C Non-Voting Preferred Stock or exercise of any Warrants, to the extent that, after giving effect to such attempted conversion set forth on an applicable Notice of Conversion (as defined in the Certificate of Designation) with respect to the Series C Preferred Stock or to such exercise, such Holder would be a beneficial owner of Common Stock beneficially owned by the Holder for purposes of Section 13(d) or Section 16 of the Exchange Act and the applicable rules and regulations of the Commission would beneficially own a number of shares of Common Stock in excess of the Beneficial Ownership Limitation.

     


     

    CUSIP No.  05338F306
     SCHEDULE 13G
    Page 4 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    David Kroin
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) x
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    114,775
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    114,775
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    114,775*
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.99%
    12
    TYPE OF REPORTING PERSON
     
    IN, HC
    * Includes 1,940.68125 Series C Non-Voting preferred stock which may be converted to common stock at a conversion ratio of 1 Series C Non-Voting preferred stock to 1,000 common stock and 1,164,408 warrants exercisable to common stock, both subject to a 9.99% Beneficial Ownership Limitation. The Issuer shall not effect any conversion of any share of Series C Non-Voting Preferred Stock or exercise of any Warrants, to the extent that, after giving effect to such attempted conversion set forth on an applicable Notice of Conversion (as defined in the Certificate of Designation) with respect to the Series C Preferred Stock or to such exercise, such Holder would be a beneficial owner of Common Stock beneficially owned by the Holder for purposes of Section 13(d) or Section 16 of the Exchange Act and the applicable rules and regulations of the Commission would beneficially own a number of shares of Common Stock in excess of the Beneficial Ownership Limitation.
     


     

     

    CUSIP No. 05338F306
     SCHEDULE 13G
    Page 5 of 9 Pages

     

    Item 1.(a) Name of Issuer

    AVALO THERAPEUTICS, INC.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    540 Gaither Road, Suite 400

    Rockville, Maryland 20850

    Item 2.(a) Names of Persons Filing:

    (i) Deep Track Capital, LP

    (ii) Deep Track Biotechnology Master Fund, Ltd.

    (iii) David Kroin 

      

    Item 2.( b) Address of Principal Business Office:

    (i) 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830

    (ii) c/o Walkers Corporate Limited, 190 Elgin Ave, George Town, KY1-9001, Cayman Islands

    (iii) c/o Deep Track Capital, LP, 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830

      

    Item 2.(c) Citizenship:

    (i) Delaware

    (ii) Cayman Islands

    (iii) United States

      

    Item 2.(d) Title of Class of Securities

    Common Stock, $0.001 Par Value (the “Common Stock”)

     

    Item 2.(e) CUSIP No.:

    05338F306

     

    CUSIP No.  05338F306
     SCHEDULE 13G
    Page 6 of 9 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
       

     

     Not Applicable

     

     

    CUSIP No. 05338F306
     SCHEDULE 13G
    Page 7 of 9 Pages

     

     

    Item 4. Ownership

    Information with respect to the Reporting Persons' ownership of the Common Stock as of April 5, 2024, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person.

    The amount beneficially owned by each Reporting Person is determined based on 1,148,905 Common Stock.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 05338F306
     SCHEDULE 13G
    Page 8 of 9 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: April 5, 2024

     

     

     

     

    Deep Track Capital, LP

           
      By:  /s/ David Kroin
        David Kroin, Managing Member of the General Partner of the Investment Adviser
           
     

    Deep Track Biotechnology Master Fund, Ltd.

     

     

     
      By:  /s/ David Kroin
        David Kroin, Director
           
     

    David Kroin

           
      By:  /s/ David Kroin
        David Kroin
           
     
    CUSIP No. 05338F306
     SCHEDULE 13G
    Page 9 of 9 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: April 5, 2024

     

     

    Deep Track Capital, LP

           
      By:  /s/ David Kroin
        David Kroin, Managing Member of the General Partner of the Investment Adviser
           
     

    Deep Track Biotechnology Master Fund, Ltd.

     

     

     
      By:  /s/ David Kroin
        David Kroin, Director
           
     

    David Kroin

           
      By:  /s/ David Kroin
        David Kroin
           
    Get the next $AVTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AVTX

    DatePrice TargetRatingAnalyst
    3/25/2025$36.00Buy
    Stifel
    3/25/2025$23.00Buy
    Jefferies
    2/28/2025$48.00Overweight
    Piper Sandler
    2/21/2025$18.00Outperform
    Wedbush
    12/19/2024$40.00Buy
    BTIG Research
    10/24/2024Neutral
    H.C. Wainwright
    4/16/2024$35.00Perform → Outperform
    Oppenheimer
    3/3/2022$5.00 → $0.75Buy → Hold
    Jefferies
    More analyst ratings

    $AVTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

      WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

      3/26/25 7:00:00 AM ET
      $AVTX
      $BHVN
      $COLL
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Reports 2024 Financial Results and Recent Business Updates

      Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy Officer Cash on hand of approximately $135 million as of December 31, 2024 expected to provide runway into at least 2027 WAYNE, Pa. and ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and year-end financial results for 2024. "2024 was a transformational year for Avalo, and I am proud of the accomplishments the team has made in a short amount of time," said Dr. Garry Neil,

      3/20/25 7:00:00 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer

      WAYNE, Pa. and ROCKVILLE, Md., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Jennifer Riley as Chief Strategy Officer, effective January 1, 2025. In this newly created role, Ms. Riley will oversee corporate strategy and commercial and product pipeline planning, with a goal of driving growth and innovation across the organization. "We are thrilled to welcome Jennifer to Avalo in the newly established role of Chief Strategy Officer," said Dr. Garry Neil, Chief Executive Officer and Chairman of the Board. "Jennifer brings extensive leadership

      1/2/25 7:00:00 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Almenoff June Sherie bought $12,750 worth of shares (1,000 units at $12.75) (SEC Form 4)

      4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      11/14/24 5:21:55 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Avalo Therapeutics Inc.

      SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

      11/14/24 6:23:00 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Avalo Therapeutics Inc.

      SC 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)

      11/14/24 12:05:55 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Avalo Therapeutics Inc.

      SC 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)

      11/7/24 5:00:07 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Chan Mitchell converted options into 3,167 shares (SEC Form 4)

      4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      4/1/25 8:06:11 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Goldman Jonathan converted options into 3,167 shares (SEC Form 4)

      4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      4/1/25 4:55:44 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Truex Samantha converted options into 3,167 shares (SEC Form 4)

      4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      4/1/25 4:44:14 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Avalo Therapeutics to Participate in The Citizens Life Sciences Conference

      WAYNE, Pa. and ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Dr. Garry Neil, Chief Executive Officer of Avalo, will present at the Citizens Life Sciences Conference in New York on Thursday, May 8, 2025, at 3:00 pm ET. Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days. About Avalo Therapeutics Avalo Therapeutics is a clinical stage biotechnology company

      4/30/25 7:00:00 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

      WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

      3/26/25 7:00:00 AM ET
      $AVTX
      $BHVN
      $COLL
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Reports 2024 Financial Results and Recent Business Updates

      Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy Officer Cash on hand of approximately $135 million as of December 31, 2024 expected to provide runway into at least 2027 WAYNE, Pa. and ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and year-end financial results for 2024. "2024 was a transformational year for Avalo, and I am proud of the accomplishments the team has made in a short amount of time," said Dr. Garry Neil,

      3/20/25 7:00:00 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTX
    SEC Filings

    See more
    • Avalo Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)

      5/8/25 7:02:47 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Avalo Therapeutics Inc.

      DEFA14A - Avalo Therapeutics, Inc. (0001534120) (Filer)

      5/1/25 7:02:41 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Avalo Therapeutics Inc.

      DEF 14A - Avalo Therapeutics, Inc. (0001534120) (Filer)

      5/1/25 7:00:42 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stifel initiated coverage on Avalo Therapeutics with a new price target

      Stifel initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $36.00

      3/25/25 8:26:24 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Avalo Therapeutics with a new price target

      Jefferies initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $23.00

      3/25/25 8:26:24 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Avalo Therapeutics with a new price target

      Piper Sandler initiated coverage of Avalo Therapeutics with a rating of Overweight and set a new price target of $48.00

      2/28/25 7:19:02 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care